Passage BIO (PASG) Total Non-Current Liabilities (2019 - 2023)
Passage BIO (PASG) posted quarterly Total Non-Current Liabilities of $40.9 million for Q1 2023, up 75.86% quarter-over-quarter from $23.3 million in Q4 2020.
Passage BIO (PASG) Total Non-Current Liabilities (2019 - 2023) Analysis & Trends
Passage BIO's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $40.9 million for Q1 2023.
- In Q1 2023, Total Non-Current Liabilities changed N/A year-over-year to $40.9 million; the TTM figure through Mar 2023 stood at $40.9 million (changed N/A YoY), while the FY2020 annual figure was $23.3 million, up 455.6% from the prior year.
- Total Non-Current Liabilities for Q1 2023 stood at $40.9 million, up from $23.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $40.9 million in Q1 2023, with the low at $4.2 million in Q4 2019.
- The 3-year median for Total Non-Current Liabilities is $17.2 million (2020), against an average of $18.1 million.
- Peak annual rise in Total Non-Current Liabilities reached 455.6% in 2020, while the deepest fall reached 455.6% in 2020.
- Passage BIO's Total Non-Current Liabilities stood at $4.2 million in 2019, then surged by 455.6% to $23.3 million in 2020, then soared by 75.86% to $40.9 million in 2023.
- Business Quant data shows PASG's Total Non-Current Liabilities at $40.9 million in Q1 2023, $23.3 million in Q4 2020, and $19.7 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.32 Bn |
| 10 | Passage BIO | 13.96 Mn | 13.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 40.89 Mn |
| Dec 31, 2020 | 23.25 Mn |
| Sep 30, 2020 | 19.75 Mn |
| Jun 30, 2020 | 14.66 Mn |
| Mar 31, 2020 | 5.72 Mn |
| Dec 31, 2019 | 4.19 Mn |